Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omegaven in Colon Cancer Surgery
NCT02231203Phase 4Completed
- Sponsor
- Noordwest Ziekenhuisgroep
- Start
- Oct 2014
- Primary completion
- Jun 2016
- Modality
- Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in colon cancer comparing Omegaven with Placebo (2 arms). Primary endpoint: Change in ex vivo production of pro-inflammatory cytokine IL-6 in LPS stimulated whole blood. Started Oct 2014; status: completed.
02
Drugs
eicosapentaenoic acid + docosahexaenoic acid
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT02231203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02231203.